相关实验视频
Updated: Jul 27, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
库尔库-青组合治疗活性性结肠炎患者:一项随机,双盲,安慰剂控制的试验
Shomron Ben-Horin1, Nir Salomon2, Georgios Karampekos3
1Department of Gastroenterology, Sheba Medical Center, Ramat-Gan, Israel; School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
草药组合CurQD有效治疗活性性结肠炎 (UC),在安慰剂对照试验中诱导临床反应和缓解. 这表明基碳化合物受体通路是UC的潜在治疗标.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 目前对UC的治疗有局限性和副作用.
- 需要新的UC治疗策略.
研究的目的:
- 为了评估黄素-QingDai (CurQD) 草药组合在患有活性的性结肠炎 (UC) 的患者中的疗效.
主要方法:
- 进行了一项两部分的研究:一项开放标签试验,其次是安慰剂对照试验.
- 有活性UC的患者接受了CurQD或安慰剂8周.
- 结果包括临床反应,缓解,内镜改善和便calprotectin的减少.
主要成果:
- 与安慰剂相比,CurQD在诱导临床反应 (85.7%与30.7%) 和缓解 (50%与8%) 中表现出显著的疗效.
- 在CurQD组中,客观反应,包括内镜改善 (75%与20%相比) 也显着更高.
- 独特的CurQD上调的粘膜细胞染色体P450 1A1 (CYP1A1) 表达,表明基碳化合物受体的激活.
结论:
- 草药组合CurQD有效地诱导活跃UC患者的反应和缓解.
- 基碳水化合物受体通路可能是UC的潜在治疗标.
- CurQD代表了性结肠炎的一种有前途的新型治疗选择.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

